Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd share price retreated by 7.97% to Rs 1218.55. The Company's net profit soared by 20.20% to Rs 36.6 crore, while revenue from operations improved marginally 6.73% to Rs 192.33 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.44%. It has marginally improved by 5.74% over last one week and crept higher by 0.60% in last one month while the market capitalization of Senores Pharmaceuticals Ltd has inched up 0.38% and 6.37% in the same period respectively. Profit before tax (PBT) of Senores Pharmaceuticals Ltd stood at Rs 47.58 crore in Q3 FY26, rallying 17.08% year-on-year, and jumping 20.58% quarter-on-quarter. EBITDA came in at Rs 49 crore, expanding by 71.19% YoY and declining 4.38% sequentially. Total expenses grew marginally by 6.25% to Rs 144.92 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 28.39 crore, marginally falling by 8.86% YoY, while employee benefits expense was at Rs 32.41 crore, registering a growth of 8.36% YoY. For the TTM ended FY26, revenue from operations surged 85.65% to Rs 398.25 crore, while net profit jumped 78.36% to Rs 58.34 crore, compared to previous TTM. EBITDA surged by 4460% to Rs 70.44 crore, and PBT witnessed a strong rise of 182.85% to Rs 70.57 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 45.92 crore in FY26, as against Rs 25.7 crore in FY25. Senores Pharmaceuticals Ltd rallied 57.29% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 12.76% during the same period.

Senores Pharmaceuticals Limited reported no deviation or variation in the utilization of Rs 95.004 crore raised through a preferential issue of 11,70,000 convertible equity warrants for the quarter ended September 30, 2026, according to a filing with the Bombay Stock Exchange and National Stock Exchange. The company had raised the funds on March 28, 2026, with the proceeds intended for funding working capital, product development, investment in subsidiaries, and general corporate purposes.

Senores Pharmaceuticals Limited reported no deviation or variation in the utilization of proceeds from its initial public offering during the quarter ended September 30, 2026, according to a filing with the Bombay Stock Exchange and National Stock Exchange. The company had raised Rs 500 crore through the IPO on December 26, 2024, and CARE Ratings Limited is the monitoring agency for the funds.

Senores Pharmaceuticals Ltd share price inched up 1.05% to Rs 1324.05 after the company's net profit jumped 20.20% to Rs 36.6 crore, while revenue from operations slightly gained 6.73% to Rs 192.33 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.26%. It has marginally improved by 3.87% over last one week and ticked higher by 0.06% in last one month while the market capitalization of Senores Pharmaceuticals Ltd has edged up by 10.11% and 1.73% in the same period respectively. Profit before tax (PBT) of Senores Pharmaceuticals Ltd stood at Rs 47.58 crore in Q3 FY26, surging by 17.08% year-on-year, and rallying 20.58% quarter-on-quarter. EBITDA came in at Rs 49 crore, expanding by 71.19% YoY and declining 4.38% sequentially. Total expenses posted a minor rise of 6.25% to Rs 144.92 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 28.39 crore, easing 8.86% YoY, while employee benefits expense was at Rs 32.41 crore, improving by 8.36% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 85.65% to Rs 398.25 crore, while net profit soared by 78.36% to Rs 58.34 crore, compared to previous TTM. EBITDA surged by 4460% to Rs 70.44 crore, and PBT surged 182.85% to Rs 70.57 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 45.92 crore in FY26, as against Rs 25.7 crore in FY25. Senores Pharmaceuticals Ltd rallied 69.02% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 13.45% during the same period.

Senores Pharmaceuticals Ltd share price softened by 4.79% to Rs 1252.4 after the company's net profit declined by 16.96% to Rs 30.45 crore, while revenue from operations improved marginally 2.87% to Rs 180.21 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.97 lakh crore, gaining 4.13%. It has eased by 1.18% over last one week and eased lower by 1.03% in last one month while the market capitalization of Senores Pharmaceuticals Ltd has slipped by 2.31% and 10.26% in the same period respectively. Profit before tax (PBT) of Senores Pharmaceuticals Ltd stood at Rs 39.46 crore in Q2 FY26, expanding by 48.96% year-on-year, and plunging by 16.75% quarter-on-quarter. EBITDA came in at Rs 51 crore, surging by 155.52% YoY and jumping 70.86% sequentially. Total expenses slightly declined by 0.45% to Rs 136.39 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 31.15 crore, rising 15.16% YoY, while employee benefits expense was at Rs 29.91 crore, seeing a marginal contraction of 1.35% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 85.65% to Rs 398.25 crore, while net profit jumped 78.36% to Rs 58.34 crore, compared to previous TTM. EBITDA surged by 4460% to Rs 70.44 crore, and PBT witnessed a strong rise of 182.85% to Rs 70.57 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 45.92 crore in FY26, as against Rs 25.7 crore in FY25. Senores Pharmaceuticals Ltd soared by 72.67% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.46% during the same period.

Senores Pharmaceuticals Limited announced the re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for three consecutive years, effective October 15, 2026, subject to shareholder approval, and Mr. Chetan Bipinchandra Shah as Whole Time Director for three consecutive years, effective November 10, 2026, also subject to shareholder approval, following a board meeting held on Tuesday, October 13, 2026.

Senores Pharmaceuticals Limited announced the re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for three consecutive years, effective October 15, 2026, subject to shareholder approval, and Mr. Chetan Bipinchandra Shah as Whole Time Director for three consecutive years, effective November 10, 2026, also subject to shareholder approval, following a board meeting held on Tuesday, October 13, 2026.

Senores Pharmaceuticals Limited submitted a certificate to the Bombay Stock Exchange and National Stock Exchange on October 8, 2026, confirming compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as processed by MUFG Intime India Private Limited, formerly Link Intime India Private Limited.

Senores Pharmaceuticals Limited will close its trading window for directors, promoters, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the announcement of the company’s unaudited financial results for the quarter and half-year ending September 30, 2026, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Senores Pharmaceuticals Limited announced several strategic moves, including the appointments of Dr. Viranchi Arvindbhai Shah as Director, Shilpa Shah as Company Secretary, and Rajeev Kumar as Chief Financial Officer. The company’s board approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026, granting 4,72,000 options, representing 1% of equity, to eligible employees with a potential discount of up to 50% on the market price. Furthermore, Senores Pharmaceuticals is expanding its international operations by incorporating a wholly-owned subsidiary in Mexico to distribute pharmaceutical products and establishing a subsidiary in Canada, in which it will hold at least 51% ownership, both funded through cash investments. Regulatory approvals will be obtained as required by Mexican and Canadian law.